FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist

Disclosure: S. Fansa: None. W. Ghusn: None. B. Nicolalde: None. D. Anazco: None. E. Tama: None. A. Acosta: None. M.D. Hurtado: None. Introduction: The increasing prevalences of obesity and type 2 diabetes (T2D), the “twin epidemics”, have led to the development of drugs targeting both diseases simul...

Descripción completa

Detalles Bibliográficos
Autores principales: Fansa, Sima, Ghusn, Wissam, Nicolalde, Bryan, Anazco, Diego, Tama, Elif, Acosta, Andres, Hurtado, Maria Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Adipose Tissue, Appetite, & Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554467/
http://dx.doi.org/10.1210/jendso/bvad114.088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554467/
http://dx.doi.org/10.1210/jendso/bvad114.088

Ejemplares similares